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Summary: An emerging clone, KPC-2-producing Klebsiella pneumoniae ST16, associated with 
high mortality rates in a CC258 endemic setting was identified. This clone carried KL51 capsule 
and displayed higher virulence in a Galleria larvae pathogenicity model than CC258 clones.  
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ABSTRACT 
Background: Carbapenemase-producing K. pneumoniae have become a global priority, not least 
in low-middle income countries. Here, we report the emergence and clinical impact of a novel 
KPC-K. pneumoniae ST16 clone in a Clonal Complex (CC)258 endemic setting. 
Methods: In a teaching Brazilian hospital, a retrospective cohort of adult KPC-KP bloodstream 
infections (BSI) cases (January 2014 to December 2016) was established to study the molecular 
epidemiology and its impact on outcome (30-day all-cause mortality). KPC-KP isolates were 
MLST-typed. Survival analysis between ST/CC groups and risk factors for fatal outcome 
(logistic regression) were evaluated. Representative isolates underwent whole genome 
sequencing (WGS), and had their virulence tested in a Galleria larvae model.  
Results: One hundred sixty-five unique KPC-KP BSI cases were identified. CC258 was 
predominant (66%), followed by ST16 (12%). The overall 30-day mortality rate was 60%; in 
contrast, 95% of ST16 cases were fatal. Patient’s severity scores were high and baseline clinical 
variables were not statistically different across ST’s. In multivariate analysis, ST16  
(OR 21.4; CI95% 2.3-202.8; p=0,008) and septic shock (OR 11.9; CI95% 4.2-34.1; p<0,001) 
were independent risk factors for fatal outcome. ST16 clone carried up to 14 resistance genes, 
including blaKPC-2 in an IncFIBpQIL plasmid, KL51 capsule and Yersiniabactin virulence 
determinants. ST16 clone was highly pathogenic in the larvae model. 
Conclusions: Mortality rates were high in this KPC-KP BSI cohort, where CC258 is endemic. 
An emerging ST16 clone was associated with high mortality. Our results suggest that even in 
endemic settings, highly virulent clones can rapidly emerge demanding constant monitoring. 
Keywords: Carbapenem-Resistant Enterobacteriaceae, KPC, bloodstream infections, CC258, 
Klebsiella pneumoniae  
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INTRODUCTION 
The widespread prevalence of carbapenem-resistant Enterobacteriaceae (CRE) bacteria is a 
major health challenge, as stressed by several national and international health organizations 
(WHO, CDC, Public Health England) [1-3]. CRE are often resistant to last resort antibiotics, 
including polymyxins, aminoglycosides, and tigecycline, hereby restricting therapeutic options 
available for treatment of serious infections [4]. New antibiotic options have become 
commercially available; however, these medicines are rarely available in low and middle-income 
countries due to both regulatory agencies approval delay and high cost [5, 6]. 
KPC-producing K. pneumoniae (KPC-KP) have emerged as a leading cause of hospital 
outbreaks and have become endemic in several hospitals in Southern Europe, North America, 
Latin America, Israel and China [7, 8], with most KPC-KP belonging to clonal complex 
(CC)258.  Within the CC258, ST11 and ST258 are the most prevalent Sequence Type (ST) [9]. 
ST258 is a hybrid clone mostly composed of ST11 genome and a minor part of ST442, which 
includes the capsule operon [10]. In general, ST258 has disseminated in North America, Latin 
America, and several European countries, whereas in Asia and particularly in China, ST11 is still 
the dominant clone [11, 12]. KPC-2-producing K. pneumoniae isolates are endemic in several 
Brazilian hospitals, mostly belonging to CC258, particularly ST437, ST258 (clade II) and ST11 
[13-15]. Other STs such as ST101, ST340 and ST442, have been sporadically reported [16-18]. 
Recently, an increase in the number of rapidly fatal outcomes of patients infected by KPC-KP 
was noticed by the infectious disease medical team in a 740-bed public teaching hospital located 
in the city of São Paulo, Brazil, where CC258 is endemic. Accordingly, this study was 
undertaken to understand the epidemiology of KPC-KP infections. Herein, we described the 
emergence of a new KPC-2 clone belonging to ST16 and associated with high bloodstream 
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infections (BSI) mortality rates.  
 
MATERIALS and METHODS  
Study population. We conducted a retrospective cohort study of adult KPC-KP BSI cases in a 
740-bed public teaching hospital located in São Paulo, Brazil. We retrieved the cases of KPC-KP 
BSI searching the routine microbiology laboratory database, selecting for hospitalized adult 
patients (>18 years old), who had positive blood cultures by KPC-KP, from January 2014 to 
December 2016. Unique cases of BSI with their corresponding KPC-KP isolates were included 
in the cohort, to avoid epidemiological bias. In case of sustained or recurrent bacteremia, only 
the first episode-isolate was included. Polymicrobial BSI were excluded (Supplementary Figure 
S1). This study was approved by the Hospital São Paulo/UNIFESP) Ethics Committee for 
Clinical Research (protocol 1.814.158). 
Clinical variables definitions. Epidemiological and clinical data were extracted from the medical 
records in a standardized case form. Variables definitions are available in the Supplementary 
Materials. 
Microbiological analysis and Galleria testing. Description on the initial identification, AST and 
KPC-PCR at the routine microbiology laboratory is available in Supplementary Materials. 
Frozen KPC-KP isolates were cultured, identification was confirmed by MALDI-TOF, 
Minimum Inhibitory Concentrations (MICs) were determined by either EUCAST agar dilution 
or broth microdilution [19]. Genetic relatedness was established by Spe-I Pulsed-Field Gel 
Electrophoresis (PFGE), and interpreted using Tenover criteria [20]. A total of 64 isolates 
including representatives of each CC258 PFGE pattern, and all culturable ST16 isolates were 
sequenced, by MiSeq Illumina platform. Remaining isolates were MLST-typed (Multilocus 
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Sequence Typing) by PCR [21]. When frozen isolates did not grow after subculturing, only 
MLST-typing was carried out (see Supplementary Figure S1). In vivo pathogenicity studies were 
carried out in the Galleria mellonella model following previously published protocols [22]. 
Details on the sequencing pipeline are available in Supplementary Materials and virulence 
determinants dataset in Supplementary Table 1S. 
Statistics. Kaplan-Meier survival curves (Log-rank test) were obtained with GraphPad PRISM5 
(San Diego, USA). Group comparisons were performed using Chi-square or Fisher exact-test and 
t-test or Mann-Whitney U test for categorical and continuous variables, respectively. The 
multivariable analysis to determine the impact of co-variables on 30-day mortality was carried 
out by binary logistic regression, adjusting for confounders, using IBM SPSS Statistics 25.0. 
(NY, USA). A cut-off of p=0.1 in the univariate analysis was used to select co-variables entering 
the multivariate model and the Horner-Lemeshow goodness-of-fit test was applied.  Total 
number of cases included in each analysis (taking into account missing values) is indicated in 
each table or figure. Exact p-values are indicated throughout the study (two-tailed). Statistical 
significance was established at p<0.05.  
 
RESULTS 
Overall cohort clinical data. One hundred sixty-five unique cases were included in this three-
year retrospective cohort of KPC-KP BSI. The overall patient’s epidemiological and clinical 
characteristics (including outcome and treatment) are depicted in Table 1. Patient’s median age 
was 59 years old with 54% male. The Comorbidity Charlson score median at admission was 5 
(IQR 3-7) with 39% of patients diagnosed with cancer (solid tumor or hematological 
malignancies). At the time of bacteremia onset, 56% of patients were hospitalized in ICUs. 
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Overall, 53% of patients developed septic shock. Only 9% and 38% of patients received at least 
two- and at least one-in vitro active antibiotic, respectively. All-cause mortality rates at 3 and 30 
days were 27% and 60%, respectively.  
  
Clinical analysis according to the ST. MLST typing was determined for 151 KPC-KP isolates. 
One hundred and nine patients (66%) were infected by KPC-KP isolates belonging to the CC258 
(ST258, ST11, ST437), 20 patients (12%) by ST16, and 22 patients (13%) by other STs 
(including ST307, ST15 and ST101), as shown in Figure 1. To establish whether the circulating 
clones could be associated with different mortality rates, survival analysis was performed 
comparing patients infected by ST16, versus CC258 and other STs. Strikingly, survival after 30 
days was lower for ST16-infected patients at 5% compared to any other group (p<0.0056), as 
shown in Figure 1. Indeed, 30-day all-cause mortality rate was 95% for patients infected 
by ST16 versus 57% and 68% for those infected by the CC258 and other ST’s, respectively 
(p<0.002). The 3-day all-cause mortality rates of ST16 group tended to be higher than those for 
CC258 and other ST’s group (45% versus 27% and 27%, respectively, although it did not reach 
statistical significance (Table 1). Three-day survival curves are shown in Supplementary Figure 
S2. Scores reflecting BSI severity tended to be higher in ST16 group compared to CC258, but 
not compared to other STs. The median bacteremia Pitt score was 4.5 versus 3.5 and 5 for 
patients infected by ST16, CC258 and other STs (p=0.168), respectively. Septic shock was 
observed in 70% of ST16 patients compared to 49% and 68% in CC258 and other ST’s group, 
respectively (Table 1). Baseline comparison between patient groups showed that Charlson 
comorbidity index median was 4 (IQR 3-7), 6 (IQR 3-8) and 4 (IQR 3-7) for ST16, CC258 and 
other STs groups (p=0.174), respectively. Median patients age and proportion of patients older 
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than 65 years old were comparable between groups. The proportion of patients in ICU prior to 
the BSI event (not influenced by the KPC-KP septic event) tended to be higher in the ST16 
group (not statistically significant). Trends to higher proportion of hepatobiliary disease 
(p=0.075) and hematological malignancies underlying diseases (p=0.079) were seen in ST16 
group. The antimicrobial therapy prescribed for the ST16 group showed a higher number of anti-
Gram-negative antimicrobial drugs prescribed (p=0.021) and more in vitro active antibiotics 
(p=0.080) (Table 1). Overall, ST16 infected patient’s variables were in most cases statistically 
comparable across groups. Taken together, these comparisons raise the possibility that the worse 
outcome for ST16-patients was due to a virulent clone, rather than infection of more severely ill 
patients.  
 
Mortality predictors analysis. To test this hypothesis, we performed an analysis for factors 
expected to influence 30-day mortality, including ST16 KPC-KP BSI (Table 2). The univariate 
analysis identified ST16 KPC-KP (vs non-ST16), Charlson comorbidity index, septic shock, 
mechanical ventilation, hepatobiliary underlying disease, pulmonary and abdominal BSI source 
to be risk factors. The multivariable model noteworthy confirmed ST16-KPC-KP infection (OR 
21.4; CI95% 2.3-202.8; p=0,008), and septic shock (OR 11.9; CI95% 4.2-34.1; p<0.001), among 
other co-variables, to be independently associated with 30-day fatal outcome (Table 2).  
 
ST16 BSI cases description. The clinical description and temporal distribution of the 20 ST16 
BSI cases are presented in Table 3. Notably, these 20 cases were scattered across the 2014-2016 
period and among several wards, suggesting that the ST16 clone had already spread in the 
hospital and persisted throughout the study period. Meropenem in combination with polymyxin 
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B (N=18), often associated with amikacin (N=15), was the most frequent empirical treatment 
prescribed. A significant number of patients did not have their definitive treatment adjusted due 
to early death (i.e. before antimicrobial susceptibility testing (AST) results became available) or 
due to unavailability of certain antimicrobials. Exact time from bacteremia onset to death was 
shown for the 19 deceased patients, showing a fatal outcome within one week after blood culture 
were drawn in the majority of the cases (55%). 
 
Isolates genetic relatedness, AST, antibiotic resistance genes (ARG) and plasmid 
replicons.  WGS based relatedness analysis indicated that ST16 was not genetically related to 
the CC258, suggesting the introduction of a novel clone in the CC258 endemic context 
(Supplementary Figure S3). Antimicrobial susceptibility profiles are shown in Table 4 and 
Supplementary Table S2. KPC-KP ST16 isolates were highly resistant to meropenem (MIC90, 
128 mg/L; 100% resistance) and polymyxin B (MIC90, 64 mg/L; 68.4% resistance). Although 
CC258 isolates showed slightly different resistance rates to meropenem (MIC90, 128 mg/L; 98% 
resistance) and polymyxin B (MIC90, 128 mg/L; 51% resistance), when compared to those of 
ST16, these differences were not statistically significant. In contrast, ST16 isolates were less 
resistant to aminoglycosides, amikacin (37% vs 55% resistance) and gentamicin (16% vs 86% 
resistance), than isolates belonging to the CC258. The ARG identified in the ST16 and CC258 
genomes are depicted in Figure 2. Besides blaKPC-2, found in all genomes as expected, blaCTX-M-
15, blaCTX-M-14 or blaCTX-M-2 were often present, as was blaSHV-like. Several Aminoglycoside 
modifying enzymes (AME) were identified including a subset of aac(6’)-Ib-cr, providing 
resistance to aminoglycoside and certain quinolones. Interestingly, all sequenced ST258 isolates 
carried rmtB 16S-methylase, explaining the elevated proportion of high level of aminoglycoside 
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resistance in this subgroup. No MCR encoding genes were identified. In contrast, mgrB 
alterations responsible for polymyxin resistance were found in 63% of ST16 isolates. Plasmid 
replicons were also shown in Figure 2. Within ST16 group, two genomes (P20 and P31) with 
distinct ARG and replicons profiles were fully assembled for further plasmid analysis. Both 
isolates carried blaKPC-2 on a 113kb IncFIBpQIL plasmid. The genetic context of blaKPC-2, in a 
Tn4401 transposon was compared to the context of ST258 isolates in Supplementary Figure S4.  
Interestingly, no virulence plasmid was found in these ST16 isolates. A description of the ST16 
plasmids is provided in Supplementary Table S3).  
 
Virulence factors determinants.  Virulence determinants in ST16 genomes and in CC258 
clones (ST258, ST11, ST437) in silico is also shown in Figure 2. All genomes had type-1 (fim) 
and type-3 (mrk) fimbrial adhesins as well as the urease gene cluster (ure), outer membrane 
protein (ycfM), enterobactin, wabGHN (LPS synthesis), and kpn. Yersiniabactin siderophore 
and virB1-11 type IV secretion system were present in all ST11 and in a subset of ST16 isolates 
(n=11) but not in the ST258 and ST437 isolates. Colibactin was present in all the ST11 genomes, 
while cloacin was present mainly in the ST11 and ST258 isolates. Aerobactin, salmochelin, 
hyperviscosity factors rmpA/rmpA2, the iron uptake system kfuABC and kvgAS two-component 
system were not identified in any of these 60 isolates. Distinct capsule loci (KL) were noticed for 
the KPC-KP isolates classified under different STs as shown in Figure 2 and in Supplementary 
Figure S5. A single KL was observed within ST16, ST258, and ST437 isolates that displayed 
KL51, KL107, and KL36 capsular types, respectively. In contrast, two distinct KL variants were 
detected in ST11 isolates. Twelve of the sixteen ST11 isolates showed KL64, while the 
remaining four isolates showed KL15 genotype. 
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G. mellonella virulence testing. To test virulence properties of these strains, larvae were 
infected by representative isolates of ST16 (KL51), ST258 (KL107), ST11 (KL64 and KL15), 
and ST437 (KL36). Survival of ST16-infected larvae were inferior to all other tested isolates 
even at the lowest tested inoculum (104 CFU). Of all tested isolates, the isolates P31 and P20 
ST16/KL51 were the most virulent strains in this model at all tested inocula (Figure 3 and 
Supplementary Figure S6 for complete strains set at each inoculum). 
 
DISCUSSION 
Despite its retrospective and single-center nature, this study provides a uniquely detailed clinical 
and microbiological description of a KPC-2 producing K. pneumoniae BSI cohort from a 
Brazilian hospital setting. No previous study has reported in a such comprehensive manner 
Brazilian data, although the endemicity of KPC-KP in Brazil is well established. In this study, 
CLABSI (primary BSI), lower respiratory tract, and intra-abdominal were the most frequent 
sources of KPC-KP BSI, in accordance with data from other Brazilian hospitals provided by the 
Brazilian Health Surveillance Agency (ANVISA) [http://www20.anvisa.gov.br] [23, 24]. 
Although the optimal treatment for KPC-KP BSI infections remains controversial, most experts 
recommend at least two in vitro active antimicrobials, especially when new therapeutic options 
such as ceftazidime/avibactam and meropenem/vaborbactam are not commercially available, as 
occurred in the present study period [23, 25]. Importantly, this study was not meant to evaluate 
KPC-KP therapeutic success. In fact, most patients did not receive two in vitro active drugs 
because: i) the isolates were multi-drug resistant showing high levels of resistance to meropenem 
(median MIC largely above the 32 mg/L threshold), aminoglycosides and polymyxin B; ii) new 
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E-lactam/E-lactamase inhibitor combinations and tigecycline (despite its debated efficacy for 
BSI) were not readily available; and iii) susceptibility results were often reported after patient 
death. For these reasons, it was difficult to infer the role of adequate antimicrobial therapy. 
Here we report 20 cases due to a novel KPC-KP ST16 clone, of which 19 were fatal. The ST16 
clone was not related to the CC258 isolates as shown by our phylogenetical analysis. It is not 
known when and how precisely this clone was introduced into this hospital, but our data show its 
maintenance during the study period.  The potential for clonal dissemination of KP ST16 beyond 
this institution remains uncertain. Previous reports of NDM-5-, OXA-48-, and CTX-M-5-
producing KP ST16 in Denmark, United Kingdom, and Spain, respectively, exist [26-28]. Scarce 
reports of isolated cases in the Netherlands (NDM-5) [29], Italy (NDM-1 and OXA-232) [30], 
Rio de Janeiro, Brazil (OXA-370) were also documented [31]. In contrast, ST16 KP has rarely 
been described harboring blaKPC, except for two isolates reported in Rio de Janeiro in 2008 and 
2009 (blaKPC-2) and one isolate in Israel. More recently, KPC-2-producing K. pneumoniae ST16 
was detected in another teaching hospital also located in São Paulo [32]. This study thus depicts 
the largest outbreak caused by KPC-ST16 [16, 17, 33], which is a poorly characterized clone, in 
contrast to the successful ST11, ST258, ST307 or ST15 clones (also found in this study) [9, 12, 
34-37]. 
Based on the group comparisons of baseline characteristics and on the multivariable analysis, it 
does not appear that ST16 infected more severely ill patients. Even treatment strategies of ST16-
infected patients were not statistically different compared to CC258- and other STs- (non-ST16, 
non-CC258) infected patients, with the exception of a higher number of anti-Gram negative 
antibiotics used in the ST16 group. Altogether this suggested that the ST16 clone had a high 
virulence potential. Survival curves showed lower survival of patients infected by ST16 
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compared to those infected by CC258 or other non-related CC258 clones. Both ST16 KPC-KP 
and septic shock were identified as independent risk factors for all-cause 30-day death in the 
multivariate analysis. The absence of collinearity between these co-variables suggested that 
death may not be consequent to severe sepsis only. Finally, there was a trend for more 
hepatobiliary comorbidity and abdominal BSI source in the ST16-patients group indicating that 
ST16 KPC-KP might have a particular tropism for hepatobiliary anatomical structures. These 
findings must be further addressed in prospective studies.  
In this study, the ST16 clone exhibited higher virulence in the Galleria mellonella pathogenicity 
model, killing more larvae than CC258 counterparts, including ST11, a clone harboring 
colibactin and yersiniabactin enconding genes, at all tested inocula.  Genomic analysis of 
virulence determinants showed that the ST16 isolates possessed a wide array of virulence genes 
such as KL51 capsule. In addition, a ST16 subset also possessed Yersiniabactin siderophore. 
However, it remains unclear if unknown key virulence factors were involved in ST16 virulence 
profile because neither rmpA/rmpA2 nor any known hypervirulence genes were identified.  
Some studies have reported that ST258 clone itself (but not every CC258-related clones) 
exhibited a low virulence profile in animal models [38]. This finding was corroborated by our 
Galleria results. In this cohort, the differences in mortality across STs might be the result of a 
high virulence of ST16 clone combined with the lower virulence displayed by ST258 clones.  
In conclusion, we described a virulent KPC-KP ST16 clone. This clone has emerged and 
disseminated in a hospital setting where KPC-KP CC258 is endemic. It has been identified as an 
independent risk factor for fatal outcome at 30 days. These results show that even in endemic 
settings, the epidemiological scenario can change and highly virulent clones can rapidly emerge 
demanding constant monitoring.  
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FIGURES LEGENDS 
Fig. 1. Kaplan-Meier plots showing the survival of patients following bacteremia due to KPC-
KP belonging to ST16 vs CC258 vs other ST’s (A), ST16 vs ST11, ST258, and ST437 (B), over 
30 days. Pie chart showing MLST distribution of the KPC-KP isolates in this study (C). Survival 
curves were plotted using the Kaplan-Meier method (GraphPad Software PRISM 5), p value was 
calculated by log-rank (Mantel-Cox). One patient (ST258 group) was censored. NA indicated 
isolates that were unavailable for MLST analysis. 
 
Fig. 2. Virulence, ARG and plasmid replicons of 64 sequenced KPC-KP strains of this study. 
Heatmap was generated after aligning the contigs of sequenced genomes of each strain to our 
virulence gene dataset, to Resfinder and to PlasmidFinder. Chromosomally encoded oqxAB 
genes were found in all KP genomes and were not displayed. None of these genomes was found 
to harbor MCR genes. 
 
Fig. 3. Kaplan–Meier plots showing the percent survival of G. mellonella over 72 h post 
infection with clinical isolates representative of ST16 (KL51), ST11 (KL64 or KL15), ST258 
(KL107) and ST437 (KL36) (A). Comparison of ST16/KL51 (B) and ST11/KL64 (C) isolates. 
A58300 is a ST23 K1 rmpA2-positive hypermucoviscous positive control. Survival curves were 
plotted using the Kaplan–Meier method and p value were calculated by log-rank (Mantel-Cox) 
test. Each line represents a single isolate. Data on all tested isolates are available in 
Supplementary Figure S6, here a subset is shown for clarity purpose.  
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